Is Editas Medicine (NASDAQ:EDIT) a buy in 2026?
Lean no. The Compass would trim Editas Medicine here, not add.
A pre-revenue CRISPR also-ran burning $300M a year while Verve and CRISPR Therapeutics own the franchises that matter.
Where EDIT is headed
Editas in mid-2027 looks like a science project running out of road. The reni-cel sickle cell program was effectively shelved in late 2024 when management pivoted away from ex-vivo, conceding the commercial economics to Vertex and CRISPR Therapeutics' Casgevy. That left EDIT-401, an in-vivo LDL receptor upregulation play, as the entire story. The problem is that Verve Therapeutics (now inside Eli Lilly after the 2025 acquisition) is two clinical years ahead with VERVE-102 in HeFH and ASCVD, backed by Lilly's cardiovascular sales muscle. Editas is bringing a second LDL-lowering gene therapy to a market where the first one will be commercialized by the company that owns Mounjaro.
Read the full Compass Direction on EDIT
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $2.80).
See the full EDIT analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Editas Medicine (NASDAQ:EDIT) a buy in 2026?
Lean no. The Compass would trim Editas Medicine here, not add. A pre-revenue CRISPR also-ran burning $300M a year while Verve and CRISPR Therapeutics own the franchises that matter.
What is EDIT's Compass Score?
Editas Medicine scores 26/100 on Alexandria's Compass, placing it in the "Headwinds" tier. Scores blend eight factors and update weekly.
What is the price target for EDIT?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the EDIT page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.